302 related articles for article (PubMed ID: 11743051)
21. HER-2/neu oncogene expression in advanced breast cancer.
Krogerus LA; Leivonen M
Cancer Detect Prev; 2001; 25(1):1-7. PubMed ID: 11270416
[TBL] [Abstract][Full Text] [Related]
22. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
[TBL] [Abstract][Full Text] [Related]
23. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
24. Ezrin expression predicts survival in stage IIB osteosarcomas.
Kim MS; Song WS; Cho WH; Lee SY; Jeon DG
Clin Orthop Relat Res; 2007 Jun; 459():229-36. PubMed ID: 17353802
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.
Press MF; Hung G; Godolphin W; Slamon DJ
Cancer Res; 1994 May; 54(10):2771-7. PubMed ID: 7909495
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical detection of Her-2/neu overexpression in breast carcinoma in Nigerians: a 5-year retrospective study.
Ugiagbe EE; Olu-Eddo AN; Obaseki DE
Niger J Clin Pract; 2011; 14(3):332-7. PubMed ID: 22037080
[TBL] [Abstract][Full Text] [Related]
27. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder.
Jalali Nadoushan MR; Taheri T; Jouian N; Zaeri F
Urol J; 2007; 4(3):151-4. PubMed ID: 17987577
[TBL] [Abstract][Full Text] [Related]
29. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.
Diallo R; Rody A; Jackisch C; Ting E; Schaefer KL; Kissler S; Karn T; Geddert H; Engels K; Kaufmann M; Gabbert HE; Shroyer KR; Poremba C
Hum Pathol; 2006 Feb; 37(2):205-11. PubMed ID: 16426921
[TBL] [Abstract][Full Text] [Related]
30. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
[TBL] [Abstract][Full Text] [Related]
31. Expression of HER-2/neu oncogene in normal, hyperplastic, and malignant endometrium.
Rasty G; Murray R; Lu L; Kubilis P; Benrubi G; Masood S
Ann Clin Lab Sci; 1998; 28(3):138-43. PubMed ID: 9646853
[TBL] [Abstract][Full Text] [Related]
32. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
Vincent-Salomon A; Jouve M; Genin P; Fréneaux P; Sigal-Zafrani B; Caly M; Beuzeboc P; Pouillart P; Sastre-Garau X
Cancer; 2002 Apr; 94(8):2169-73. PubMed ID: 12001113
[TBL] [Abstract][Full Text] [Related]
33. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas.
Park HR; Min K; Kim HS; Jung WW; Park YK
Pathol Res Pract; 2008; 204(8):575-82. PubMed ID: 18440723
[TBL] [Abstract][Full Text] [Related]
34. Lack of HER-2/neu overexpression in non-Hodgkin's lymphoma.
Lüftner D; Genvresse I; Geppert R; Kaufmann O; Dietel M; Possinger K
Anticancer Res; 2004; 24(5B):3233-7. PubMed ID: 15510616
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer.
Kohlberger P; Loesch A; Koelbl H; Breitenecker G; Kainz C; Gitsch G
Cancer Lett; 1996 Jan; 98(2):151-5. PubMed ID: 8556702
[TBL] [Abstract][Full Text] [Related]
36. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
[TBL] [Abstract][Full Text] [Related]
37. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
38. Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma.
Baumhoer D; Smida J; Specht K; Bink K; Quintanilla-Martinez L; Rosemann M; Siggelkow H; Nathrath WB; Atkinson MJ; Bielack S; Jundt G; Nathrath M
Hum Pathol; 2011 Jun; 42(6):859-66. PubMed ID: 21292304
[TBL] [Abstract][Full Text] [Related]
39. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.
Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M
Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827
[TBL] [Abstract][Full Text] [Related]
40. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study.
Masood S; Bui MM
Ann Clin Lab Sci; 2000 Jul; 30(3):259-65. PubMed ID: 10945565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]